Applying Chitosan-Modified Nanoemulsion in Nasal Vaccine Delivery

HAO Xin-yan, ZHANG Yuan-dong, HOU Ying-ying, SUN Xun

Abstract

To prepare a chitosan-modified cationic nanoemulsion that could be used to prolong the residence time of nasal vaccines in the nasal cavity and improve the cellular uptake efficiency so as to enhance the immune efficacy of nasal vaccines.  Methods  A nanoemulsion-based vaccine coated with chitosan was prepared, and the particle size, potential, antigen encapsulation efficiency, stability as well as cytotoxicity were examined. The uptake efficiency of vaccine on different cells and the residence time of vaccine in the nasal cavity were measured. Finally, nasal vaccine was administered on mice and the antibody levels in the serum and in the nasal lavage fluids of the immunized mice were examined.  Results  The nanoemulsion-based vaccine had an average particle size of (167.2±0.75) nm, a polydispersity index (PDI) of 0.21±0.01, and an average potential of (13.7±0.85) mV. The encapsulation efficiency of antigen was 92.7%. The nanoemulsion-based vaccine had good stability and did not show obvious cytotoxicity in Madin-Darby canine kidney (MDCK) epithelial cells. The vaccine demonstrated relatively high cellular uptake of antigens on DC2.4 and MDCK cells at (49.7±3.45)% and (59.7±2.19)%, respectively. Besides, the cationic nanoemulsion also significantly increased the residence time of the antigen, and a considerable amount of nanoemulsion-based vaccine was found remaining in the nasal cavity 60 minutes after administration. Compared with free antigen and the nanoemulsion without chitosan modification, the chitosan-modified nanoemulsion vaccine induced higher systemic and mucosal antibody levels in mice after nasal immunization (P<0.01).  Conclusion  The chitosan-modified nanoemulsion vaccine prepared in the study can enhance the immune efficacy of nasal vaccines, showing great potential to be used as a delivery carrier for nasal vaccines.

 

Keywords: Nanoemulsion, Nasal administration, Immune responses

 

Full Text:

PDF


References


LI M， WANG Y， SUN Y， et al. Mucosal vaccines: Strategies and challenges. Immunol Lett，2020，217: 116–125.

LOBAINA MATO Y. Nasal route for vaccine and drug delivery: Features and current opportunities. Int J Pharm， 2019， 572: 118813 [2021-03-15]. https://doi.org/10.1016/j.ijpharm.2019.118813.

BOYAKA P N. Inducing mucosal IgA: A challenge for vaccine adjuvants and delivery systems. J Immunol，2017，199(1): 9–16.

JIN Z， GAO S， CUI X， et al. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Int J Pharm， 2019， 572: 118731[2021-03-15]. https://doi.org/10.1016/j.ijpharm.2019.118731.

BERNOCCHI B， CARPENTIER R， BETBEDER D. Nasal nanovaccines. Int J Pharm，2017，530(1/2): 128–138.

BRITO L A， CHAN M， SHAW C A， et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther，2014，22(12): 2118–2129.

KO E J， KANG S M. Immunology and efficacy of MF59-adjuvanted vaccines. Hum Vaccin Immunother，2018，14(12): 3041–3045.

SHIM S， YOO H S. The application of mucoadhesive chitosan nanoparticles in nasal drug delivery. Mar Drugs，2020，18(12): 605.

BRUINSMANN F A， PIGANA S， AGUIRRE T， et al. Chitosan-coated nanoparticles: Effect of chitosan molecular weight on nasal transmucosal delivery. Pharmaceutics，2019，11(2): 86.

CHRISTENSEN D， BOLLEHUUS HANSEN L， LEBOUX R， et al. A liposome-based adjuvant containing two delivery systems with the ability to induce mucosal immunoglobulin A following a parenteral immunization. ACS Nano，2019，13(2): 1116–1126.

LI J， DIAZ-AREVALO D， CHEN Y， et al. Intranasal vaccination with an engineered influenza virus expressing the receptor binding subdomain of botulinum neurotoxin provides protective immunity against botulism and influenza. Front Immunol， 2015， 6: 170[2021-03-15]. https://doi.org/ 10.3389/fimmu.2015.00170.

KUMAR P， NAGARAJAN A， UCHIL P D. Analysis of cell viability by the MTT assay. Cold Spring Harb Protoc，2018，2018(6): 469–471.

LI M， ZHAO M， FU Y， et al. Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways. J Control Release，2016，228: 9–19.

DI COLA E， CANTU L， BROCCA P， et al. Novel O/W nanoemulsions for nasal administration: Structural hints in the selection of performing vehicles with enhanced mucopenetration. Colloids Surf B Biointerfaces， 2019， 183: 110439[2021-03-15]. https://doi.org/10.1016/j.colsurfb. 2019.110439.

JIANG Y， LI M， ZHANG Z， et al. Enhancement of nasal HIV vaccination with adenoviral vector-based nanocomplexes using mucoadhesive and DC-targeting adjuvants. Pharm Res，2014，31(10): 2748–2761.

LI M， LI Y， PENG K， et al. Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses. Acta Biomater， 2017，64: 237–248.

MORAN H B T ， TURLEY J L， ANDERSSON M， et al. Immunomodulatory properties of chitosan polymers. Biomaterials，2018， 184: 1–9.

LI D， FU D， KANG H， et al. Advances and potential applications of chitosan nanoparticles as a delivery carrier for the mucosal immunity of vaccine. Curr Drug Deliv，2017，14(1): 27–35.


Refbacks

  • There are currently no refbacks.